Daewoong Pharmaceutical Sustainability Profile
Daewoong Pharmaceutical Co., Ltd., commonly referred to as Daewoong, is a leading South Korean pharmaceutical company headquartered in Incheon, South Korea. Established in 1945, Daewoong has made significant strides in the pharmaceutical industry, focusing on research and development, manufacturing, and marketing of innovative medicines. The company operates extensively across Asia, Europe, and the Americas, with a diverse portfolio that includes prescription drugs, over-the-counter products, and biopharmaceuticals. Notable for its commitment to innovation, Daewoong has developed unique therapies in areas such as gastroenterology, neurology, and endocrinology. With a strong market position, Daewoong has achieved several milestones, including the successful launch of its biosimilar products, which have garnered recognition for their quality and efficacy. As a forward-thinking organisation, Daewoong Pharmaceutical continues to contribute to global health advancements.
DitchCarbon Score
How does Daewoong Pharmaceutical's carbon action stack up? DitchCarbon scores companies based on their carbon action and commitment to reducing emissions. Read about our methodology to learn more.
Industry Average
Mean score of companies in the Pharmaceutical Preparation Manufacturing industry. Comparing a company's score to the industry average can give you a sense of how well the company is doing compared to its peers.
Industry Benchmark
Daewoong Pharmaceutical's score of 30 is higher than 52% of the industry. This can give you a sense of how well the company is doing compared to its peers.
Let us know if this data was useful to you
Daewoong Pharmaceutical's reported carbon emissions
In 2024, Daewoong Pharmaceutical reported total carbon emissions of approximately 32,500,000 kg CO2e, comprising about 9,675,000 kg CO2e from Scope 1 and about 23,296,000 kg CO2e from Scope 2 emissions. This marks a slight decrease from 2023, where total emissions were around 34,706,000 kg CO2e, with Scope 1 emissions at approximately 10,184,000 kg CO2e and Scope 2 emissions at about 24,522,000 kg CO2e. The company has not disclosed any Scope 3 emissions data, indicating a potential area for future reporting and improvement. Daewoong Pharmaceutical has not set specific reduction targets or initiatives under the Science Based Targets initiative (SBTi) or other climate pledges, which may limit its ability to demonstrate a proactive approach to climate commitments. Overall, Daewoong Pharmaceutical's emissions data reflects its ongoing operations in the pharmaceutical sector, with a focus on managing its direct and indirect emissions. The absence of reduction targets suggests that the company may need to enhance its climate strategy to align with industry standards and expectations.
Unlock detailed emissions data
Access structured emissions data, company-specific emission factors, and source documents
| 2020 | 2021 | 2022 | 2023 | 2024 | |
|---|---|---|---|---|---|
| Scope 1 | - | 0,000,000 | 00,000,000 | 00,000,000 | 0,000,000 |
| Scope 2 | 35,843,000 | 00,000,000 | 00,000,000 | 00,000,000 | 00,000,000 |
| Scope 3 | - | - | - | - | - |
How Carbon Intensive is Daewoong Pharmaceutical's Industry?
How Carbon Intensive is Daewoong Pharmaceutical's Location?
Daewoong Pharmaceutical's Climate Goals (2030 & 2050)
Climate goals typically focus on 2030 interim targets and 2050 net-zero commitments, aligned with global frameworks like the Paris Agreement and Science Based Targets initiative (SBTi) to ensure alignment with global climate goals.
Daewoong Pharmaceutical has not publicly committed to specific 2030 or 2050 climate goals through the major frameworks we track. Companies often set interim 2030 targets and long-term 2050 net-zero goals to demonstrate measurable progress toward decarbonization.
